Patents by Inventor Ake Lindahl
Ake Lindahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220273765Abstract: The present invention concerns a composition comprising a peptide, a saccharide and a lipid vehicle, which is suitable for topical delivery.Type: ApplicationFiled: April 24, 2020Publication date: September 1, 2022Applicant: Follicum ABInventors: Åke Lindahl, Jan Alenfall, Maria Ekblad
-
Publication number: 20170258914Abstract: There is provided a pharmaceutical composition for the treatment of fungal infection of the nail comprising a anti-fungal allylamine compound present in an amount of about 10%, an organic acid or an ester thereof, a diol and a sequestering agent where the pharmacological composition is essentially water-freeType: ApplicationFiled: December 20, 2016Publication date: September 14, 2017Inventor: Ake Lindahl
-
Patent number: 9561279Abstract: There is provided a pharmaceutical composition for the treatment of fungal infection of the nail comprising a antifungal allylamine compound present in an amount of about 10%, an organic acid or an ester thereof, a diol and a sequestering agent where the pharmacological composition is essentially water-free.Type: GrantFiled: November 6, 2014Date of Patent: February 7, 2017Assignee: Moberg Pharma ABInventor: Ake Lindahl
-
Publication number: 20150250878Abstract: There is provided a pharmaceutical composition for the treatment of fungal infection of the nail comprising a antifungal allylamine compound present in an amount of about 10%, an organic acid or an ester thereof, a diol and a sequestering agent where the pharmacological composition is essentially water-freeType: ApplicationFiled: November 6, 2014Publication date: September 10, 2015Inventor: Ake Lindahl
-
Patent number: 8952070Abstract: There is provided a pharmaceutical composition for the treatment of fungal infection of the nail comprising a anti-fungal allylamine compound present in an amount of about 10%, an organic acid or an ester thereof, a diol and a sequestering agent where the pharmacological composition is essentially water-free.Type: GrantFiled: February 10, 2012Date of Patent: February 10, 2015Assignee: Moberg Pharma ABInventor: Ake Lindahl
-
Patent number: 8921428Abstract: There is provided a pharmaceutical composition for the treatment of fungal infection of the nail comprising a anti-fungal allylamine compound present in an amount of about 10%, an organic acid or an ester thereof, a diol and a sequestering agent where the pharmacological composition is essentially water-free.Type: GrantFiled: February 10, 2012Date of Patent: December 30, 2014Assignee: Moberg Pharma ABInventor: Ake Lindahl
-
Publication number: 20140031430Abstract: There is provided a pharmaceutical composition for the treatment of fungal infection of the nail comprising a anti-fungal allylamine compound present in an amount of about 10%, an organic acid or an ester thereof, a diol and a sequestering agent where the pharmacological composition is essentially water-freeType: ApplicationFiled: February 10, 2012Publication date: January 30, 2014Applicant: Moberg Pharma ABInventor: Ake Lindahl
-
Publication number: 20130324502Abstract: A dermal, transdermal and/or mucosal formulation for topical application on skin, comprising an active pharmaceutical ingredient and a pharmaceutically acceptable solvent, and an anti-solvent; wherein the active pharmaceutical ingredient is soluble in the solvent in the absence of the anti-solvent, and wherein the active pharmaceutical ingredient is substantially in the solid state in the presence of the anti-solvent. A method for increasing the stability of an active pharmaceutical ingredient.Type: ApplicationFiled: February 10, 2012Publication date: December 5, 2013Applicant: MOBERG PHARMA ABInventors: Åke Lindahl, Peter Kaufmann
-
Patent number: 8431140Abstract: Single phase pharmaceutical compositions for topical application, in addition to kits and methods of use and administration are provided. The compositions comprise a biologically active agent; a delivery vehicle comprising at least a non-polymeric crystallization inhibitor and a film-former; and a volatile solvent; wherein the biologically active agent is present in the composition in a subsaturated state, the biologically active agent is present in the delivery vehicle in a supersaturated state, and the crystallization inhibitor is capable of delaying crystallization of the biologically active agent in the delivery vehicle. Biologically active agents include terbinafine and acyclovir. Treatments for onychomycosis and Varicella zoster infection, HSV-I infection or HSV-2 infection are provided.Type: GrantFiled: June 14, 2007Date of Patent: April 30, 2013Assignees: Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd.Inventors: Ake Lindahl, Birgitta Svensson, Anna Holmberg, Johan Engblom
-
Publication number: 20120129942Abstract: A stable antifungal composition for topical application on a nail comprising a diol component, an organic acid component, a volatile vehicle, an antifungal agent and a keratolytic agent; the active compound and the keratolytic agent are soluble in the composition in the absence of said volatile vehicle, and wherein at least one in the group selected from the antifungal agent and the keratolytic agent is present in solid state in the composition in the presence of said volatile vehicle. Preferred ingredients include propylene glycol, lactic acid, ethyl acetate, urea and terbinafine or naftifine.Type: ApplicationFiled: August 13, 2010Publication date: May 24, 2012Applicant: MOBERG DERMA ABInventor: Ake Lindahl
-
Publication number: 20100279934Abstract: Aspects of this invention relate to compositions and methods for the stabilization, storage, and delivery of biologically active agents, in particular peptides and nucleic acids. Particularly preferred embodiments include compositions that comprise a recombinant naturally occurring human hepatocyte growth factor (HGF), such as dHGF, a five amino acid truncated HGF variant, and at least one monoglyceride that remains in crystalline form at body temperature. Optionally, a gelling agent such as, hydroxyethylcellulose, and/or an antipathogenic compound (e.g., bupivacaine) can be included in the composition. Methods of use of these compositions to improve, ameliorate, or treat skin conditions are also embodiments.Type: ApplicationFiled: December 19, 2008Publication date: November 4, 2010Applicant: KRINGLE PHARMA, INC.Inventor: Ake Lindahl
-
Publication number: 20100010052Abstract: A topical composition comprising a dihydropyridine calcium antagonist, a stiffening agent and a release modifier. The stiffening agent comprises a fatty alcohol, a fatty acid sorbitane ester, or a fatty acid glycerol ester, having a hydrocarbon chain containing 12 to 22 carbon atoms and having a melting point of about 45 to 750° C. The release modifier comprises a fatty alcohol, a fatty alcohol glycol ether, a fatty acid alkyl ester, a fatty acid glycerol ester, or a fatty acid sorbitane ester, having a hydrocarbon chain containing 12 to 18 carbon atoms and having a melting point of about ?10 to 400° C. Use of such a composition for the treatment and/or prophylaxis of a dermal or mucosal disorder, preferably an anorectal disorder associated with high anal pressure or anal sphincter spasm.Type: ApplicationFiled: August 31, 2007Publication date: January 14, 2010Applicant: MOBERG DERMA ABInventors: Johan Engblom, Birgitta Svensson, Anette Abrahamsson, Åke Lindahl
-
Publication number: 20090247529Abstract: Single phase pharmaceutical compositions for topical application, in addition to kits and methods of use and administration are provided. The compositions comprise a biologically active agent; a delivery vehicle comprising at least a non-polymeric crystallization inhibitor and a film-former; and a volatile solvent; wherein the biologically active agent is present in the composition in a subsaturated state, the biologically active agent is present in the delivery vehicle in a supersaturated state, and the crystallization inhibitor is capable of delaying crystallization of the biologically active agent in the delivery vehicle. Biologically active agents include terbinafine and acyclovir. Treatments for onychomycosis and Varicella zoster infection, HSV-1 infection or HSV-2 infection are provided.Type: ApplicationFiled: June 14, 2007Publication date: October 1, 2009Applicants: DR. REDDY'S LABORATORIES LTD., DR. REDDY'S LABORATORIES, INC.Inventors: Ake Lindahl, Birgitta Svensson, Anna Holmberg, Johan Engblom
-
Publication number: 20080089939Abstract: Provided is a solid stick topical composition containing a corticosteroid. The solid stick also contains petrolatum, wax, propyleneglycol and emulsifier. The solid stick is contained in a protective covering so that during application it does not come in contact with the hand holding the stick.Type: ApplicationFiled: June 28, 2007Publication date: April 17, 2008Inventors: Ake Lindahl, Johan Gullberg
-
Publication number: 20040091539Abstract: Provided is a solid stick topical composition containing a corticosteroid. The solid stick also contains petrolatum, wax, propyleneglycol and emulsifier. The solid stick is contained in a protective covering so that during application it does not come in contact with the hand holding the stick.Type: ApplicationFiled: November 13, 2002Publication date: May 13, 2004Inventors: Ake Lindahl, Johan Gullberg
-
Patent number: 6413496Abstract: A device for providing pharmaceutical doses comprising a container, filled with a pharmaceutical composition including a pharmaceutically active agent in a solution of liquified 1,1,1,2-tetrafluoroethane (HFC-134a), or 1,1,1,2,3,3,3 heptafluoropropane (HFC-227) and a carrier. The carrier can be a pharmaceutically acceptable alcohol, polyol, (poly)alkoxy derivative, fatty acid alkyl ester, polyalkylene glycol, or dimethyl sulphoxide. The device includes a valve arranged for delivering aerosol doses of said pharmaceutical composition to the exterior of the container, and at least a portion of the device is formed from a polyester.Type: GrantFiled: June 4, 1999Date of Patent: July 2, 2002Assignee: Biogland Ireland (R&D) LimitedInventors: Michael Goodman, Ake Lindahl
-
Patent number: 6348203Abstract: A viscous hydrogel composition, for use in a topical treatment of a skin condition involving dry or inflammed skin, comprising an antimicrobially active nitroimidazole drug, a water miscible alkylene glycol, a bydroxyalkyl cellulose gelling agent and water, buffered to have a physiologically acceptable pH and a method of making the same.Type: GrantFiled: February 11, 2000Date of Patent: February 19, 2002Assignee: Biogland Ireland (R&D) LimitedInventors: Michael Goodman, Ake Lindahl
-
Patent number: 4822535Abstract: A method of producing small spherical polymer particles from systems containing two liquid phases, the one phase of which contains one or more dissolved substances and is dispersed in the form of small droplets in the other phase to form an emulsion, whereafter the droplets are converted to a solid form. The liquid phases used are two mutually immiscible aqueous phases.Type: GrantFiled: June 26, 1986Date of Patent: April 18, 1989Assignee: Norsk Hydro A.S.Inventors: Bo Ekman, Ake Lindahl